Biohaven (BHVN) Short-term Investments (2022 - 2026)
Biohaven (BHVN) posted Short-term Investments of $74.7 million for Q1 2026, down 16.19% sequentially from $89.2 million in Q4 2025, and down 66.68% YoY from $224.3 million in Q1 2025.
Analysis
Biohaven (BHVN) Short-term Investments (2022 - 2026) Analysis & Trends
Biohaven has reported Short-term Investments for 5 years, with the latest figure at $74.7 million in Q1 2026.
- Quarterly Short-term Investments fell 66.68% year-over-year to $74.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $74.7 million (down 66.68% YoY) and the FY2025 annual result came in at $89.2 million, down 76.95% from the prior year.
- Short-term Investments declined to $74.7 million in Q1 2026 per BHVN's latest filing, from $89.2 million in the prior quarter.
- Over five years, Short-term Investments peaked at $386.9 million in Q4 2024 and troughed at $28000.0 in Q3 2023.
- A 5-year average of $155.6 million and a median of $117.1 million in 2023 frame the typical range for Short-term Investments.
- The sharpest annual moves came in 2024 and 2025: Short-term Investments surged 1051421.43% in 2024, then slumped 76.95% in 2025.
- Over 5 years, Short-term Investments stood at $260.5 million in 2022, then tumbled by 48.78% to $133.4 million in 2023, then jumped by 189.96% to $386.9 million in 2024, then plunged by 76.95% to $89.2 million in 2025, then slipped by 16.19% to $74.7 million in 2026.
- According to Business Quant data, Short-term Investments over the past three periods registered $74.7 million, $89.2 million, and $75.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Biohaven | 2.37 Bn | 2.10 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 29.83 Mn |
| Mar 31, 2026 | 74.74 Mn |
| Dec 31, 2025 | 89.18 Mn |
| Sep 30, 2025 | 75.37 Mn |
| Jun 30, 2025 | 239.18 Mn |
| Mar 31, 2025 | 224.33 Mn |
| Dec 31, 2024 | 386.86 Mn |
| Sep 30, 2024 | 294.43 Mn |
| Jun 30, 2024 | 197.80 Mn |
| Mar 31, 2024 | 100.71 Mn |
| Dec 31, 2023 | 133.42 Mn |
| Sep 30, 2023 | 128.90 Mn |
| Jun 30, 2023 | 187.50 Mn |
| Mar 31, 2023 | 263.00 Mn |
| Dec 31, 2022 | 260.46 Mn |